Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)Hai‐Dong Zhu, Jian Wang, Hai-Liang Li et al.|Signal Transduction and Targeted Therapy|2023Cited by 295
Irradiation stent with 125I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trialGao‐Jun Teng, Yang Zhao, Rui Li et al.|International Journal of Surgery|2023Cited by 29
Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective studyWei-Li Xia, Hai-Liang Li, Xiaohui Zhao et al.|Frontiers in Oncology|2022Cited by 25
Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective StudyWei-Li Xia, Hai-Liang Li, Xiao-Hui Zhao et al.|Clinical and Translational Gastroenterology|2023Cited by 15
Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinomaYuan Guo, Hai-Liang Li, Ru-Chun Li et al.|World Journal of Gastrointestinal Oncology|2024Cited by 11